Finoriq research workspace
Beam Therapeutics Inc. (BEAM) SEC Filings & Filing Highlights
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic. Review BEAM SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
- Company
- Beam Therapeutics Inc. (BEAM)
- Ticker
- BEAM
- Market Cap
- $2.7B
- Latest Price
- $26.2
- Industry
- Biotech & Pharma
Beam Therapeutics Inc. (BEAM) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Beam Therapeutics Inc. (BEAM).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesOn June 3, 2026, Beam Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following... | 8-K5.07 | 2026-06-08 |
| Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | 8-K2.02 | 2026-05-07 |
| Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License fro...Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kobe University | 8-K1.02 | 2026-03-05 |
| Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New...Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Ph... | 8-K2.02 | 2026-02-24 |
| Beam Therapeutics Inc.: Material agreementOn February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreem... | 8-K1.01 | 2026-02-24 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.